药物涂层球囊失效后高剂量药物涂层球囊重复治疗的效果
该单中心观察性研究分析了2018年12月至2021年12月间89例因股腘动脉药物涂层球囊(DCB)再狭窄病变接受DCB重复治疗的病例,经倾向性评分匹配比较 high-dose 与 low-dose DCB 重复治疗的临床结局。结果显示高剂量DCB组1年免于再狭窄、免于再次靶病变血运重建和免于主要不良肢体事件均显著优于低剂量组,而免于再闭塞无显著差异。
要点
- 股腘动脉DCB再狭窄病变行高剂量DCB重复治疗,1年免于再狭窄率90.4% vs 低剂量40.9%(p=0.034)。
- 高剂量组1年免于再次TLR为95.0% vs 低剂量53.3%(p=0.025)。
- 高剂量组1年免于MALE为95.0% vs 低剂量54.7%(p=0.025),免于再闭塞无显著差异。
核心结论
- 对于股腘动脉DCB再狭窄病变,高剂量DCB重复治疗较低剂量DCB重复治疗获得更有利的结局。
研究设计与样本
- 单中心观察性研究,使用2018年12月至2021年12月间677例连续接受股腘动脉血管内介入治疗的症状性外周动脉疾病患者的临床数据库。
- 其中89例因股腘动脉DCB再狭窄病变接受DCB重复治疗的病例被分析,采用倾向性评分匹配。
- 主要终点为再狭窄(re-restenosis),次要终点为再次靶病变血运重建(TLR)、再闭塞和主要不良肢体事件(MALE)。
主要发现
- 倾向性评分匹配后,高剂量DCB组1年免于再狭窄率显著高于低剂量DCB重复治疗组(90.4% vs 40.9%,p=0.034)。
- 高剂量DCB组1年免于再次TLR显著高于低剂量组(95.0% vs 53.3%,p=0.025)。
- 高剂量DCB组1年免于MALE显著高于低剂量组(95.0% vs 54.7%,p=0.025)。
- 两组1年免于再闭塞率无显著差异(100.0% vs 84.0%,p=0.99)。
- 基线特征或围手术期结局对高剂量与低剂量DCB和再狭窄风险之间的关联均无显著交互作用。
临床怎么用
- 作者认为,该发现可能也是日常临床实践中对股腘动脉DCB再狭窄病变选择高剂量DCB重复治疗的理由。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although the optimal treatment for femoropopliteal (FP) drug-coated balloon (DCB) restenosis lesions remains debatable, the effectiveness of DCB repetition for DCB restenosis has been reported. However, the optimal DCB repetition strategy is not yet established. Thus, this study aimed to compare the clinical outcomes of high-dose DCB repetition with those of low-dose DCB repetition for FP DCB restenosis lesions. MATERIALS AND METHODS: This single-center, observational study used a clinical database of 677 consecutive patients undergoing FP endovascular intervention for symptomatic peripheral artery disease between December 2018 and December 2021. Of these patients, 89 cases treated with DCB repetition for FP DCB restenosis lesions were analyzed. The primary endpoint was recurrent restenosis (re-restenosis) and the secondary endpoints were recurrent target-lesion revascularization (TLR), re-occlusion, and major adverse limb events (MALE) obtained using propensity score matching. Interaction analysis was also performed to explore the effects of the baseline characteristics on the association between high- and low-dose DCB with restenosis risk. RESULTS: After propensity score matching, high-dose DCB demonstrated a significantly higher freedom from re-restenosis compared with low-dose DCB repetition at 1 year (90.4% vs 40.9%, p=0.034). In addition, freedom from re-TLR and MALE at 1 year was significantly higher in the high-dose DCB group (95.0% vs 53.3%, p=0.025; 95.0% vs 54.7%, p=0.025, respectively). Conversely, freedom rates from re-occlusion were not significantly different between the 2 groups (100.0% vs 84.0%, p=0.99). No baseline characteristics or perioperative outcomes had any significant interaction effect on the association of high-dose DCB versus low-dose DCB with restenosis risk. CONCLUSION: For FP DCB restenosis lesions, high-dose DCB repetition offered more favorable outcomes than low-dose DCB repetition.Clinical ImpactThis study revealed that for femoropopliteal drug-coated balloon (DCB) restenosis lesions, high-dose DCB repetition obtained more favorable outcomes than low-dose DCB repetition. In addition, there was no significant interaction effect on the association of high- versus low-dose DCB with re-restenosis risk for the baseline characteristics and perioperative outcomes. This finding might be also a reason for choosing high-dose DCB repetition for FP DCB restenosis lesions in daily clinical practice.
引用
- Tomoi Y, Takahara M, Soga Y, et al. Effect of High-Dose Drug-Coated Balloon Repetition After Drug-Coated Balloon Failure. J Endovasc Ther. 2023. PMID: 38009011. doi:10.1177/15266028231214167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。